Absci vs bioAffinity Technologies
ABSI and BIAF side by side, both in engineering, accounting, research, management, and related services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ABSI and BIAF compare
Absci is the larger company, worth 565 times as much as bioAffinity Technologies ($1.5B against $2.6M).
bioAffinity Technologies grew revenue faster over the last twelve months (−18.5% versus −47.2% for Absci).
bioAffinity Technologies keeps more of each dollar of sales as profit, with a net margin of −279% compared with −8451% at Absci.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ABSI | BIAF |
|---|---|---|
| Size and price | ||
| Market cap | $1.5B | $2.6M |
| Share price | $8.45 | $2.20 |
| Change, 1 year | 149% | −93.2% |
| Change, 5 years | −23.5% | – |
| Beta (5Y) | 2.19 | −1.10 |
| Employees | 140 | 57 |
| StockData Score | ||
| Total score | 5 | 5 |
| Valuation score | 0 | 3 (better) |
| Growth score | 0 | 0 |
| Performance score | 0 | 0 |
| Health score | 5 (better) | 2 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 975× | 0.5× (better) |
| P/B | 6.6× | 0.7× (better) |
| FCF yield | −7.8% (better) | −508% |
| Fair value | – | $11.85 |
| Margin of safety | – | 81.4% |
| Growth | ||
| Revenue growth (TTM) | −47.2% | −18.5% (better) |
| Revenue growth, 5Y average | −10.1% | – |
| Profitability | ||
| Operating margin | −8812% | −246% (better) |
| Net margin | −8451% | −279% (better) |
| FCF margin | −7563% | −236% (better) |
| Return on equity | −58.6% (better) | −240% |
| Return on invested capital | −242% (better) | −694% |
| Financial health | ||
| Debt / equity | 0.00 | 0.05 (better) |
| Interest coverage | −2569.4× | −270.9× (better) |
| Current ratio | 9.64 (better) | 1.51 |
| Altman Z-score | 36.44 (better) | −19.56 |
| Piotroski F-score | 3 (better) | 2 |
| Dividends and buybacks | ||
| Buyback yield | −7.6% | – |
| Shareholder yield | −7.6% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 88.3% | 11.1% |
| Held by insiders | 15.5% | – |
| Insider net buying, 12 months | $801K | – |
| Short interest, % of float | 24.7% | – |
Go deeper
- ABSI stock overview
- ABSI income statement
- ABSI valuation and score
- BIAF stock overview
- BIAF income statement
- BIAF valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.